Performance evaluation of an amplicon-based next-generation sequencing panel for BRCA1 and BRCA2 variant detection

Area of Science:

• Genetics
• Molecular Diagnostics
• Cancer Genomics

Background:

• Next-generation sequencing (NGS) technologies are advancing for BRCA1/2 genotyping.
• Various amplicon-based NGS tests are available for clinical use.
• Evaluating new diagnostic panels is crucial for accurate genetic variant detection.

Purpose of the Study:

• To assess the performance of the AmpliSeq for Illumina BRCA Panel for detecting clinically significant BRCA variants.
• To compare the AmpliSeq panel's results against another amplicon-based NGS test and Sanger sequencing.
• To evaluate the reliability of the AmpliSeq panel for hereditary breast/ovarian cancer syndrome (HBOC) diagnostics.

Main Methods:

• Retrospective review of BRCA test results from patients suspected of HBOC.
• Inclusion of 96 samples with 100 clinically significant BRCA1 and BRCA2 variants.
• Duplicate testing using the AmpliSeq panel and comparison with previous NGS results and Sanger sequencing confirmation.

Main Results:

• The AmpliSeq panel detected 99 out of 100 variants, achieving 99% sensitivity and 100% specificity.
• One variant (BRCA1 c.3627dupA) was detected in one repeat but not the other.
• Automated variant nomenclature was consistent with Human Genome Variation Society standards for most variants.

Conclusions:

• The AmpliSeq for Illumina BRCA Panel exhibits satisfactory analytical performance.
• The panel demonstrates high sensitivity and specificity for BRCA1/2 variant detection.
• This NGS test is a reliable tool for genetic testing in hereditary cancer syndromes.